东诚药业1月9日获融资买入1350.56万元，融资余额11.33亿元

Group 1 - On January 9, Dongcheng Pharmaceutical's stock increased by 0.55%, with a trading volume of 162 million yuan. The financing buy amount was 13.51 million yuan, while the financing repayment was 15.99 million yuan, resulting in a net financing buy of -2.49 million yuan. The total financing and securities balance reached 1.13 billion yuan [1] - The financing balance of Dongcheng Pharmaceutical is 1.13 billion yuan, accounting for 9.47% of the circulating market value, which is above the 80th percentile level over the past year, indicating a high level [1] - On the same day, the company had a securities lending repayment of 300 shares and a securities lending sell of 9,500 shares, with a selling amount of 137,800 yuan. The remaining securities lending volume was 29,600 shares, with a balance of 429,200 yuan, which is below the 30th percentile level over the past year, indicating a low level [1] Group 2 - As of September 30, the number of shareholders of Dongcheng Pharmaceutical was 24,600, an increase of 4.51% compared to the previous period. The average circulating shares per person decreased by 4.32% to 30,191 shares [2] - For the period from January to September 2025, Dongcheng Pharmaceutical achieved an operating income of 2.04 billion yuan, a year-on-year decrease of 5.52%. The net profit attributable to the parent company was 149 million yuan, a year-on-year decrease of 10.64% [2] - Since its A-share listing, Dongcheng Pharmaceutical has distributed a total of 1 billion yuan in dividends, with 293 million yuan distributed in the last three years [3]